Ayahuasca is a plant-based psychedelic brew originating from Amazonian traditions, prepared by combining two plants: Banisteriopsis caapi (the vine, which contains beta-carboline MAO inhibitors) and Psychotria viridis (the leaf, which contains DMT, dimethyltryptamine). Without the MAOI from the vine, orally consumed DMT would be broken down by gut enzymes before reaching the brain.
Pharmacologically, ayahuasca is primarily a serotonergic compound. DMT acts as a potent agonist at 5-HT2A serotonin receptors. the same receptor target as psilocybin and LSD. producing intense visionary states, emotional amplification, and altered perception. The harmala alkaloids from the vine contribute anxiolytic and antidepressant properties of their own.
A single ayahuasca ceremony typically lasts 4 to 6 hours. Therapeutic programs often involve multiple ceremonies over consecutive nights or across multiple weeks. The setting is traditionally shamanic or ceremonial, facilitated by a trained curandero or retreat guide, with varying levels of medical oversight depending on the program.
The therapeutic profile of ayahuasca centers on emotional and psychological processing. Many participants report profound confrontations with repressed memories, unresolved grief, relational patterns, and spiritual or existential themes. The experience is frequently accompanied by intense physical purging, vomiting is common, considered by many traditions to be part of the healing process.
Research supports ayahuasca's potential for treatment-resistant depression, PTSD, and anxiety. particularly where emotional processing and insight are therapeutic mechanisms. However, there is a critical pharmacological limitation for patients seeking addiction treatment: ayahuasca has no direct opioid receptor activity. It cannot interrupt physical opioid withdrawal, eliminate physical drug cravings rooted in receptor dependency, or provide the neurological reset that physically dependent patients require.
Key limitation: Ayahuasca is not effective for physical opioid withdrawal and is not a clinical treatment for opioid use disorder. Patients in active opioid dependence require a medicine that directly engages opioid receptor systems.
Ibogaine is an indole alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to the rainforests of Central West Africa, primarily Gabon, Cameroon, and the Republic of Congo. It has been used ceremonially in the Bwiti tradition for centuries as a rite of passage and healing tool. Its modern clinical application emerged in the 1960s when Howard Lotsof, himself an opioid-dependent patient, discovered that a single ibogaine experience dramatically eliminated his withdrawal symptoms.
Unlike ayahuasca, ibogaine is a multi-receptor compound. It acts simultaneously on mu-opioid receptors (without producing dependence), NMDA glutamate receptors (involved in sensitization and craving memory), serotonin transporters, sigma-2 receptors (linked to neuroplasticity), and kappa-opioid receptors. This pharmacological breadth is what makes ibogaine uniquely suited to addiction medicine. no single neurotransmitter system is left untouched.
The ibogaine experience lasts 18 to 36 hours, significantly longer than ayahuasca, and contains both a pharmacological and a visionary component. The first phase involves rapid interruption of opioid withdrawal (in dependent patients) and intense neurological activity. The second phase, as the acute effects taper, involves the deeply introspective, memory-processing dimension that parallels some of what ayahuasca facilitates serotonergically.
Ibogaine's metabolite, noribogaine, has a long half-life and remains active in the brain for days to weeks after treatment, continuing to modulate opioid receptors and promoting the secretion of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), proteins that support the formation of new neural pathways. This post-treatment neuroplasticity window is a defining feature of ibogaine with no equivalent in ayahuasca pharmacology.
Because ibogaine prolongs the cardiac QTc interval, it carries a real cardiac risk that must be managed through medical pre-screening, including a resting EKG, electrolyte panel, and cardiac history review. At MindScape Retreat, continuous cardiac monitoring is maintained throughout the session under the supervision of Dr. Omar Calderon, M.D. This medical requirement distinguishes ibogaine from ayahuasca, which carries its own safety considerations (primarily MAOI drug interactions) but does not require the same cardiac infrastructure.
Key distinction: Ibogaine directly eliminates physical opioid withdrawal, something no other psychedelic medicine can accomplish. It is the only compound known to interrupt the mu-opioid receptor cycle while simultaneously inducing a visionary healing state.
| Factor | Ibogaine (MindScape) | Ayahuasca |
|---|---|---|
| Source Plant | Tabernanthe iboga (West Africa) | Banisteriopsis caapi + Psychotria viridis (Amazon) |
| Primary Receptor System | Multi-receptor: mu-opioid, NMDA, serotonin, sigma-2, kappa | Serotonergic: 5-HT2A agonist (via DMT) + MAO inhibition |
| Duration Per Session | 18 to 36 hours (single sustained experience) | 4 to 6 hours per ceremony |
| Number of Sessions | Typically one, occasionally a booster | Multiple ceremonies over days or weeks |
| Opioid Withdrawal Relief | Direct, eliminates acute withdrawal within hours | None. no opioid receptor activity |
| Addiction Treatment Capability | Strong clinical evidence for opioid, stimulant, alcohol dependency | Reported benefit for behavioral patterns; not proven for physical dependency |
| PTSD / Depression Efficacy | Significant, neuroplasticity + visionary processing | Significant, serotonergic emotional processing |
| Physical Purging | Uncommon, nausea managed medically | Common and expected, vomiting considered part of the process |
| Cardiac Risk | Yes. QTc prolongation requires EKG pre-screening | Lower cardiac risk; MAOI drug interactions are significant |
| Medical Oversight Required | Yes, continuous cardiac monitoring during session | Variable. often ceremonial with limited medical supervision |
| Setting | Medical clinic with trained physicians and nursing staff | Shamanic/ceremonial, retreats, jungle settings, or urban groups |
| Legal Status | Legal in Mexico, administered at MindScape Retreat, Cozumel | Legal in Peru, Brazil, Portugal, Netherlands; variable globally |
| Research Base | Growing. Phase 2 trials underway, Stanford, MAPS, Johns Hopkins | Growing. Brazilian studies, MAPS Phase 2 for MDD |
Ayahuasca primarily activates the serotonin system (5-HT2A). the same pathway as psilocybin and LSD, producing visionary and emotional experiences. Ibogaine engages at least five distinct receptor systems simultaneously, including the mu-opioid receptor that drives physical drug dependence. This difference in receptor scope determines which conditions each medicine is suited to treat.
Ayahuasca excels at emotional, psychological, and spiritual healing. particularly where serotonergic processing is the therapeutic mechanism. Ibogaine treats a broader clinical scope: physical drug dependence, opioid withdrawal interruption, neurological conditions like Parkinson's, and psychological healing, all in a single session. For addiction medicine, these scopes are not interchangeable.
Ayahuasca retreats vary widely in medical oversight, from shamanic ceremonies with no clinical staff to retreat centers with trained nurses. Ibogaine requires formal medical infrastructure: pre-treatment EKG, cardiac clearance, continuous monitoring during the 18 to 36 hour session, and on-site emergency capability. At MindScape, every patient is treated within a full medical protocol, not a spiritual retreat model.
A typical ayahuasca therapeutic program involves multiple ceremonies. often 3 to 7 sessions spread over days or weeks, allowing cumulative processing across experiences. Ibogaine is designed as a single high-impact intervention: one session interrupts the neurochemical basis of addiction, followed by a weeks-long neuroplasticity window that supports integration and lasting change. For time-constrained patients, this distinction matters significantly.
Ibogaine and ayahuasca should never be administered simultaneously or in close succession . the pharmacological interactions between these two compounds are not fully characterized and pose serious safety concerns. Both affect serotonin systems, and combining them risks serotonin syndrome, cardiac events, and unpredictable neurological effects.
However, a sequential approach. with sufficient time between treatments, is something a meaningful number of patients explore. In clinical practice, some patients who have completed ibogaine treatment at a facility like MindScape Retreat subsequently pursue ayahuasca ceremonies months later as a deepening integration tool.
The logic behind this sequence is pharmacologically sound: ibogaine addresses the neurobiological roots of addiction and produces a window of heightened neuroplasticity. Once the patient is physically free from dependence, the serotonergic emotional processing that ayahuasca facilitates can complement the psychological integration work already begun. The two medicines are not competitors. they operate on different systems and serve different roles in a healing journey.
“MindScape Retreat specializes in ibogaine. it is our clinical focus, and it is where our expertise, safety protocols, and 900+ patient outcomes have been built. We respect ayahuasca as a legitimate plant medicine and do not discourage patients from exploring it as part of their ongoing integration journey. But for physical addiction and the neurobiological reset our patients need, ibogaine is in a category of its own.”
. Dr. Omar Calderon, M.D., Clinical Director, MindScape Retreat
Ibogaine's multi-receptor mechanism allows us to target the specific neurobiological systems driving each patient's addiction. Unlike serotonergic medicines, ibogaine directly engages the opioid receptors responsible for physical dependence, making outcomes measurable, trackable, and tied to verifiable neurochemical change.
With over 900 patients treated under Dr. Omar Calderon, M.D., MindScape has built a clinical database of outcomes across opioid, stimulant, alcohol, and co-occurring psychiatric presentations. We know what ibogaine achieves, what its limits are, and how to structure the treatment protocol for the best probability of lasting recovery.
Ibogaine's cardiac requirements are real, and they are manageable with proper infrastructure. Every MindScape patient undergoes pre-treatment EKG, QTc assessment, and electrolyte screening. Continuous cardiac monitoring is maintained by our nursing team throughout the full 18 to 36 hour session. Safety is the non-negotiable foundation of everything we do.
No other plant medicine provides ibogaine's unique combination: opioid receptor modulation without creating dependency, NMDA-mediated craving interruption, BDNF/GDNF neuroplasticity induction, and a visionary healing experience, all in a single session. This combination is the reason ibogaine remains in a clinical category that ayahuasca, psilocybin, and ketamine do not occupy.
Our admissions team will review your medical history, current medications, and treatment goals to determine if ibogaine is the right intervention for you. Every consultation is confidential, with no obligation. Dr. Omar Calderon, M.D. and our clinical team have guided 900+ patients through successful treatment in Cozumel, Mexico.